Searched for
MANKIND SHARE PRICE
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Is your portfolio FII-proof? 7 stocks Jefferies says can defy the $53 billion foreign selloffForeign investors have divested $53 billion from Indian equities since late 2024, leading to underperformance against emerging markets. Dom...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...
- Stock picks of the week: 6 stocks with consistent score improvement and upside potential of up to 29%Usually, official talks are mere formalities – meetings to ink things that have already been agreed upon. The one scheduled between the US ...
- Time to increase the risk quotient? Maybe, but selectively: 5 large-caps from different sectors with upside potential of up to 28%With Israel refusing to play ball and Iran maintaining its vice-like hold on the Strait of Hormuz, the ceasefire declared by US President T...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%The market is again abuzz with the possibility of peace in the Gulf. This has, however, happened in the past. There is, thus, no point in g...
- Mankind Pharma shares jump 2% as Morgan Stanley initiates coverage with Overweight call. Check target, upsideMankind Pharma share price surged 2% after Morgan Stanley initiated coverage with an 'Overweight' rating and a Rs 2,500 target price, citin...
- Mankind Pharma shares in focus after Q3 net profit rises 8%YoY to Rs 414 croreThe company reported an 8% year-on-year rise in Q3FY26 net profit to Rs 414 crore, while revenue grew 11.5% to Rs 3,567 crore, led by solid...
- Mankind Pharma stock falls 3% as PE investors likely sell 1.3 crore sharesPE firm ChrysCapital's affiliate entity Beige Ltd was reported to have issued a term sheet via its broker to sell up to 1.16 crore shares o...
- Mankind Pharma shares jump 9% post Q1 earnings. Should you buy?The domestic business reported a robust 14% YoY growth in the quarter. The secondary sales saw an impressive growth of 12.5%, thereby outpe...
- Mankind Pharma draws rush of buy calls on 57% jump since IPOInvestors are scrambling to purchase shares in drug and condom maker, Mankind Pharma Ltd., which has had the most analyst coverage of any n...
- Mankind Pharma shares plunge over 5% as I-T department raids Delhi officeShares of Mankind Pharma dropped 5.5% following news of India's income tax department conducting searches at its Delhi office. Its shares a...
- Mankind Pharma shares tank over 6% a day after solid debut. Time to buy?Shares of Mankind Pharma fell more than 6%, a day after its listing on the Indian stock exchanges at a premium. The company's IPO was the l...
- Macquarie initiates coverage on Mankind Pharma, sees 30% upsideMankind Pharma derives 98% of its revenue from the domestic pharma market. Within its domestic business, 90% of its revenue comes from pres...
- Mankind Pharma IPO now open: Here's how it stacks up against its peersThe Issue comprises an offer for sale (OFS) of about 40 million equity shares and will be open for subscription till April 27.
Load More
